FISH analysis for amplifications of EGFR (aka ERBB1 or HER1) can be used for prognostic and therapeutic consideration in various solid tumors such as glioblastoma, lung, colorectal, gastric, and breast. Amplifications are typically associated with poor prognosis, while presence and level of amplification may not correspond to level of protein expression or response to anti-EGFR therapy in gastrointestinal cancers. High gene copy number may indicate poor prognosis in gastric and triple-negative breast cancers. However, its role in treating breast cancer and other tumors with EGFR/HER2/HER4 inhibitors is under investigation. The proto-oncogene MET c-MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. Overexpression of MET has been observed in variety of neoplasms such as kidney, lung, head and neck, ovary, breast, thyroid, brain, stomach, pancreas and colon. MET gene amplification, detected by FISH, has been associated with an unfavorable prognosis in non-small cell lung cancer (NSCLC) and resistance to EGFR inhibitors.
Also known as: EGFR Amplification FISH.